HC Wainwright Issues Optimistic Estimate for POAI Earnings

Predictive Oncology Inc. (NASDAQ:POAI) – Equities research analysts at HC Wainwright raised their Q4 2025 earnings per share (EPS) estimates for Predictive Oncology in a research report issued to clients and investors on Friday, November 15th. HC Wainwright analyst S. Ramakanth now forecasts that the medical instruments supplier will earn $0.06 per share for the quarter, up from their prior estimate of $0.05. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Predictive Oncology’s current full-year earnings is ($2.03) per share. HC Wainwright also issued estimates for Predictive Oncology’s FY2026 earnings at $0.08 EPS, FY2027 earnings at $0.27 EPS and FY2028 earnings at $0.46 EPS.

Predictive Oncology Stock Down 7.2 %

Shares of POAI stock opened at $0.69 on Monday. The stock has a fifty day moving average of $0.75 and a 200 day moving average of $1.06. Predictive Oncology has a 52 week low of $0.55 and a 52 week high of $3.76. The firm has a market capitalization of $4.58 million, a price-to-earnings ratio of -0.23 and a beta of 1.14.

Predictive Oncology Company Profile

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.